A Rare Case of Tremor Induces by Cycloserine in Drug-Resistant Tuberculosis Patient
DOI:
https://doi.org/10.37506/mvhwz607Keywords:
Drug-Resistant Tuberculosis, Cycloserine, Tremor, Adverse Drug ReactionAbstract
Background: Tuberculosis is a contagious disease that generated by Mycobacterium tuberculosis. Drug-Resistant tuberculosis (DR-TB) is inculpated the use of the second-line anti-tubercular treatment which is associated with many drug side effects or so called, Adverse Drug Reactions (ADR). Cycloserine (Cs) is an important drug against drug resistant tuberculosis (DR-TB). Cycloserine has been used in tuberculosis therapy since the late 1950s. Identical with most drug, Cycloserine can cause many Adverse Drug Reactions (ADR).
Case Illustration: A 23-year-old woman diagnosed with drug-resistant tuberculosis is undergoing long-term treatment. The patient received treatment for DR-TB with the Bdq-Lfx-Cfz-Cs-E regimen. After the patient underwent the 10th month of advanced phase treatment, the patient complained of shaking in both hands (tremors). The tremor is felt to be more severe in the right hand and the patient cannot grip objects tightly.
Discussion: Cycloserine (Cs) play an important role in second-line drug management of DR-TB. Cs-Induced psychosis and other neurological side-effects can be detrimental towards patients yet they are rarely reports in DR-TB cases. Cs is correlated with severe psychiatric cases and Central Nervous System related ADRs. Cs-associated ADR is most likely because of production of gamma-aminobutyric acid as a result of inhibition of glutamic decarboxylase. Study Shown that among 132 patients who reported side effects in the cycloserine group, 2 (1.4%) experienced major side effects, namely tremors. Side effects possibly or probably related to Cs appeared after a median of 71 days (range 10–331 days) of Cs treatment.
Conclusion: the drug side effects such as tremors are very rare in drug-resistant tuberculosis patients. In this case, the patient's complaint of tremors could be caused by cycloserine as an anti-tuberculosis drug.
References
Kusmiati T, Nugroho N, Charisma A, Soedarsono S. Drug-resistant tuberculosis treatment outcomes: A comparison between primary health care and hospital ambulatory treatment. 2020;161–9.
Kementrian Kesehatan Republik Indonesia. Laporan Program Penanggulangan Tuberkulosis 2021. Jakarta: Kementrian Kesehatan RI; 2022.
Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the Mycobacterium tuberculosis D-alanine: D-alanineligase, a target of the anti tuberculosis drug D-cycloserine. AntimicrobAgents Chemother. 2011;55(1):291–301.
Li Y, Wang F, Zhu M, He G, Chen X. Cycloserine For Treatment Of Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study In China. Dovepress Infection and Drug Resistance. 2019;12:721–31.
Intini E, Kishore G, Richeldi L, Udwadia ZF. Neuropsychiatric reactions induced by cycloserine in the treatment of multi drug-resistant tuberculosis: what an Indian female patient tells us. BMJ Case Rep. 2019 Dec 4;12(12):230993.
Singhal P, Lunia P, Salgia K, Syed I. Incidence of cycloserine induced neurotoxicity in drug resistant TB patients attending a tertiary care hospital. In: Tuberculosis. European Respiratory Society; 2020. p. 1593.
Yadav S, Rawal G. Adverse Drug Reactions Due To Cycloserine On The Central Nervous System In The Multidrug-Resistant Tuberculosis Cases: A Case Series. PAMJ Clinical Medicine [Internet]. 2019 [cited 2024 May 18];1(25). Available from: https://www.clinical-medicine.panafrican-med-journal.com
Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med [Internet]. 2015 [cited 2024 May 18]; Availablefrom: www.perspectivesinmedicine.org
World HealthOrganization. Global Tuberculosis Report 2020. Geneva: WHO; 2020.
Meijer IA. VPS13D Movement Disorder. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Gripp KW, Amemiya A, editors. GeneReviews®. Seattle: Universityof Washington; 2019.
Kementrian Kesehatan Republik Indonesia. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat Di Indonesia. Jakarta: Kementrian Kesehatan RI; 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Palmalina Anggita, Citra Dewi Ameliya, Nur Prasetyo Nugroho
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.